Adjuvant Nivolumab Plus Ipilimumab vs Placebo for Localised Renal Cell Carcinoma After Nephrectomy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial
Lancet 2023 Feb 09;[EPub Ahead of Print], RJ Motzer, P Russo, V Grünwald, Y Tomita, B Zurawski, O Parikh, S Buti, P Barthélémy, JC Goh, D Ye, A Lingua, JB Lattouf, L Albigès, S George, B Shuch, J Sosman, M Staehler, S Vázquez Estévez, B Simsek, J Spiridigliozzi, A Chudnovsky, A BexFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.